Please assess the completion status of the following clinical trial:

Trial Title: A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult volunteers with a body mass index (ie, the relationship between a person's height and weight) between 18 and 30 kg/m2 (inclusive), and body weight not less than 50 kg~* Have normal blood pressure between 90 and 140 mmHg systolic and \<=90 mmHg diastolic~* Female volunteers must have a negative serum beta human chorionic gonadotropin (hCG) pregnancy test at screening and a negative urine pregnancy test on the day before each treatment period~* Female volunteers must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if of childbearing potential and sexually active, be practicing an effective method of birth control before entry and throughout the study~* Male volunteers must agree to use an adequate contraception method as deemed appropriate by the investigator~Exclusion Criteria:~* Currently have, or have a history of clinically significant medical illness that the investigator considers should exclude the volunteer or that could interfere with the interpretation of the study results~* Have a history of drug or alcohol abuse within the past 1 year or a history of clinically significant allergies, especially known hypersensitivity or intolerance to milk products~* Have a history of smoking or use of nicotine-containing substances within the previous 2 months~* Have had major or traumatic surgery within 12 weeks before screening or preplanned surgery or procedures that would interfere with the conduct of the study~* known allergy to the study drug or any of the excipients of the formulation or known allergy to heparin or history of heparin-induced thrombocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment sequence AEBDC (Type: EXPERIMENTAL): None
- Treatment sequence BACED (Type: EXPERIMENTAL): None
- Treatment sequence CBDAE (Type: EXPERIMENTAL): None
- Treatment sequence DCEBA (Type: EXPERIMENTAL): None
- Treatment sequence EDACB (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).